Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AUPH shares.
View AUPH analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued twelve-month price objectives for Aurinia Pharmaceuticals' shares. Their AUPH share price targets range from $8.00 to $13.00. On average, they anticipate the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 107.9% from the stock's current price.
View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts.

Aurinia Pharmaceuticals' stock was trading at $8.99 at the start of the year. Since then, AUPH shares have decreased by 46.5% and is now trading at $4.81.
View the best growth stocks for 2024 here.

Aurinia Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 12,240,000 shares, an increase of 14.9% from the March 15th total of 10,650,000 shares. Based on an average trading volume of 2,340,000 shares, the days-to-cover ratio is presently 5.2 days. Currently, 9.6% of the shares of the stock are short sold.
View Aurinia Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AUPH earnings forecast.

Aurinia Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) released its quarterly earnings data on Thursday, February, 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.03. The biotechnology company had revenue of $45.10 million for the quarter, compared to analyst estimates of $45 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 20.10% and a negative net margin of 44.45%. The firm's revenue for the quarter was up 58.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.18) earnings per share.

Virtus LifeSci Biotech Products ETF holds 42,195 shares of AUPH stock, representing 1.16% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Aurinia Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sunbelt Securities Inc. (0.13%) and Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include David RW Jayne, George M Milne Jr, Jill Leversage, Joseph M Miller, Joseph P Hagan, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.